---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-119939"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:17:42.056520+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Q1 net loss $13.7M; advancing IKT-001 PAH Ph2b trial in H2 2025

## Summary
- Net loss $13.7M ($0.15/share) vs $4.6M ($0.73) in Q1 2024; includes $7.4M non-cash acquisition charge for CorHepta.
- R&D expenses $10.5M (incl. $7.4M IPR&D charge); SG&A $5.2M; cash $93.2M at March 31, 2025.
- Appointed new CEO (Mark Iwicki), President/Head of R&D (Chris Cabell), CSO (John Adams), CFO (David McIntyre).
- IKT-001 Phase 2b PAH study design finalizing; trial initiation expected H2 2025; FDA 'Study May Proceed' received Sept 2024.

## SEC filing metadata
- accession: 0001193125-25-119939
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312525119939/0001193125-25-119939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312525119939/d940084d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-119939
- JSON: https://secwatch.observer/filing/0001193125-25-119939.json
- Plain text: https://secwatch.observer/filing/0001193125-25-119939.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.